The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018
| Autor: | Adrienna Bingham, Marc Brisson, Jean-François Laprise, Sagar Kumar, Thomas L. Gift, Ian H. Spicknall, Paul G. Farnham, Samuel T Eppink, Thomas A. Peterman, Harrell W. Chesson, Kristen Kreisel, Henry Roberts |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Microbiology (medical)
Gonorrhea Psychological intervention Dermatology urologic and male genital diseases 03 medical and health sciences 0302 clinical medicine Environmental health medicine 030212 general & internal medicine health care economics and organizations 030505 public health Chlamydia Trichomoniasis business.industry Incidence (epidemiology) Public Health Environmental and Occupational Health virus diseases Hepatitis B medicine.disease female genital diseases and pregnancy complications Infectious Diseases Syphilis 0305 other medical science business Medical costs |
| Zdroj: | Sexually Transmitted Diseases. 48:215-221 |
| ISSN: | 1537-4521 0148-5717 |
| DOI: | 10.1097/olq.0000000000001380 |
| Popis: | Background We estimated the lifetime medical costs attributable to sexually transmitted infections (STIs) acquired in 2018, including sexually acquired human immunodeficiency virus (HIV). Methods We estimated the lifetime medical costs of infections acquired in 2018 in the United States for 8 STIs: chlamydia, gonorrhea, trichomoniasis, syphilis, genital herpes, human papillomavirus (HPV), hepatitis B, and HIV. We limited our analysis to lifetime medical costs incurred for treatment of STIs and for treatment of related sequelae; we did not include other costs, such as STI prevention. For each STI, except HPV, we calculated the lifetime medical cost by multiplying the estimated number of incident infections in 2018 by the estimated lifetime cost per infection. For HPV, we calculated the lifetime cost based on the projected lifetime incidence of health outcomes attributed to HPV infections acquired in 2018. Future costs were discounted at 3% annually. Results Incident STIs in 2018 imposed an estimated $15.9 billion (25th-75th percentile: $14.9-16.9 billion) in discounted, lifetime direct medical costs (2019 US dollars). Most of this cost was due to sexually acquired HIV ($13.7 billion) and HPV ($0.8 billion). STIs in women accounted for about one fourth of the cost of incident STIs when including HIV, but about three fourths when excluding HIV. STIs among 15- to 24-year-olds accounted for $4.2 billion (26%) of the cost of incident STIs. Conclusions Incident STIs continue to impose a considerable lifetime medical cost burden in the United States. These results can inform health economic analyses to promote the use of cost-effective STI prevention interventions to reduce this burden. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|